NASDAQ:FBRX Forte Biosciences (FBRX) Stock Price, News & Analysis → The asset beating inflation by 4x (From Colonial Metals) (Ad) Free FBRX Stock Alerts $0.71 +0.02 (+2.88%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$0.69▼$0.7350-Day Range$0.62▼$0.7852-Week Range$0.38▼$1.11Volume11,841 shsAverage Volume24,602 shsMarket Capitalization$26.02 millionP/E RatioN/ADividend YieldN/APrice Target$2.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Forte Biosciences alerts: Email Address Forte Biosciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside285.1% Upside$2.75 Price TargetShort InterestHealthy0.09% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.32Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.46) to ($0.45) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.28 out of 5 starsMedical Sector1819th out of 5,430 stocksPharmaceutical Preparations Industry817th out of 2,526 stocks 3.3 Analyst's Opinion Consensus RatingForte Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageForte Biosciences has only been the subject of 1 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted0.09% of the outstanding shares of Forte Biosciences have been sold short.Short Interest Ratio / Days to CoverForte Biosciences has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Forte Biosciences has recently decreased by 3.23%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldForte Biosciences does not currently pay a dividend.Dividend GrowthForte Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for FBRX. Previous Next 3.0 News and Social Media Coverage News SentimentForte Biosciences has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Forte Biosciences this week, compared to 0 articles on an average week.Search Interest1 people have searched for FBRX on MarketBeat in the last 30 days. MarketBeat Follows3 people have added Forte Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Forte Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders10.53% of the stock of Forte Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions77.63% of the stock of Forte Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Forte Biosciences are expected to grow in the coming year, from ($0.46) to ($0.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Forte Biosciences is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Forte Biosciences is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioForte Biosciences has a P/B Ratio of 0.74. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchGold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).See his free reveal right here. About Forte Biosciences Stock (NASDAQ:FBRX)Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.Read More FBRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FBRX Stock News HeadlinesMay 2, 2024 | americanbankingnews.comTraders Purchase High Volume of Forte Biosciences Call Options (NASDAQ:FBRX)April 10, 2024 | benzinga.comForte Biosciences Stock (NASDAQ:FBRX), Analyst Ratings, Price Targets, PredictionsMay 4, 2024 | Stansberry Research (Ad)Gold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).April 8, 2024 | markets.businessinsider.comBuy Recommendation for Forte Biosciences on Strong Potential of Novel FB-102 Treatment and Market PositionMarch 19, 2024 | investorplace.comFBRX Stock Earnings: Forte Biosciences Reported Results for Q4 2023March 18, 2024 | businesswire.comForte Biosciences, Inc. Announces 2023 Results and Provides Business UpdateDecember 12, 2023 | morningstar.comForte Biosciences Inc Ordinary SharesDecember 9, 2023 | finance.yahoo.comWe Think Forte Biosciences (NASDAQ:FBRX) Needs To Drive Business Growth CarefullyMay 4, 2024 | Stansberry Research (Ad)Gold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).November 15, 2023 | morningstar.comForte Biosciences Inc Ordinary Shares FBRXNovember 14, 2023 | msn.comForte Biosciences GAAP EPS of -$0.26November 13, 2023 | finance.yahoo.comForte Biosciences, Inc. Announces Third Quarter 2023 Results and Provides Business UpdateSeptember 14, 2023 | benzinga.comISS and Glass Lewis Recommend Forte Biosciences Stockholders Vote FOR Boardroom Change at the Company's Upcoming Annual MeetingSeptember 14, 2023 | finance.yahoo.comISS and Glass Lewis Recommend Forte Biosciences Stockholders Vote FOR Boardroom Change at the Company’s Upcoming Annual MeetingSeptember 6, 2023 | finance.yahoo.comConcerned Stockholders of Forte Biosciences and Its Independent Director Candidates Share Key Facts that Reinforce the Need for Urgent Change in the Company’s BoardroomAugust 25, 2023 | businesswire.comConcerned Stockholders of Forte Biosciences File Definitive Proxy Statement and Send Letter to StockholdersAugust 25, 2023 | 247wallst.comCamac Fund Now Owns 4.3% of Forte BiosciencesAugust 14, 2023 | finance.yahoo.comForte Biosciences, Inc. Announces Second Quarter 2023 Results and Provides Business UpdateAugust 3, 2023 | benzinga.comChief Financial Officer At This Health Care Company Buys $149K of StockAugust 1, 2023 | finance.yahoo.comForte Biosciences, Inc. Announces $25 Million Financing and R&D Update for FB-102July 4, 2023 | finance.yahoo.comThis Forte Biosciences Insider Increased Their Holding In The Last YearMay 24, 2023 | finance.yahoo.comWe're Not Very Worried About Forte Biosciences' (NASDAQ:FBRX) Cash Burn RateMay 19, 2023 | finance.yahoo.comForte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing RulesMay 15, 2023 | finance.yahoo.comForte Biosciences, Inc. Announces First Quarter 2023 Results and Provides Business UpdateApril 6, 2023 | msn.comUnusual Call Option Trade in Forte Biosciences (FBRX) Worth $2.50KMarch 31, 2023 | finance.yahoo.comForte Biosciences, Inc. Announces Full Year 2022 Results and Provides Business UpdateJanuary 28, 2023 | seekingalpha.comFBRX Forte Biosciences, Inc.See More Headlines Receive FBRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Forte Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/18/2024Today5/04/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:FBRX CUSIPN/A CIK1419041 Webwww.fortebiorx.com Phone(310) 618-6994FaxN/AEmployees9Year FoundedN/APrice Target and Rating Average Stock Price Target$2.75 High Stock Price Target$2.75 Low Stock Price Target$2.75 Potential Upside/Downside+285.1%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-31,480,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-94.27% Return on Assets-81.36% Debt Debt-to-Equity RatioN/A Current Ratio10.45 Quick Ratio10.45 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.97 per share Price / Book0.74Miscellaneous Outstanding Shares36,440,000Free Float32,605,000Market Cap$26.02 million OptionableOptionable Beta0.46 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Paul A. Wagner Ph.D. (Age 54)CEO, President & Chairman Comp: $914.5kMr. Antony A. Riley CPA (Age 57)Chief Financial Officer Comp: $532kMr. Christopher RoenfeldtChief Operating OfficerMr. Steven Ruhl (Age 67)Chief Technical Officer Key CompetitorsAcasti PharmaNASDAQ:ACSTUnity BiotechnologyNASDAQ:UBXAprea TherapeuticsNASDAQ:APRENRx PharmaceuticalsNASDAQ:NRXPSensei BiotherapeuticsNASDAQ:SNSEView All CompetitorsInsiders & InstitutionsCable Car Capital LLCBought 2,031,987 shares on 2/20/2024Ownership: 5.593%Paul A WagnerBought 10,000 shares on 12/18/2023Total: $7,500.00 ($0.75/share)Paul A WagnerBought 10,520 shares on 12/13/2023Total: $7,364.00 ($0.70/share)Paul A WagnerBought 25,000 shares on 12/11/2023Total: $16,250.00 ($0.65/share)Paul A WagnerBought 36,203 shares on 12/7/2023Total: $20,997.74 ($0.58/share)View All Insider TransactionsView All Institutional Transactions FBRX Stock Analysis - Frequently Asked Questions Should I buy or sell Forte Biosciences stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Forte Biosciences in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" FBRX shares. View FBRX analyst ratings or view top-rated stocks. What is Forte Biosciences' stock price target for 2024? 2 equities research analysts have issued twelve-month price targets for Forte Biosciences' shares. Their FBRX share price targets range from $2.75 to $2.75. On average, they expect the company's share price to reach $2.75 in the next year. This suggests a possible upside of 285.1% from the stock's current price. View analysts price targets for FBRX or view top-rated stocks among Wall Street analysts. How have FBRX shares performed in 2024? Forte Biosciences' stock was trading at $0.8217 on January 1st, 2024. Since then, FBRX shares have decreased by 13.1% and is now trading at $0.7141. View the best growth stocks for 2024 here. Are investors shorting Forte Biosciences? Forte Biosciences saw a drop in short interest in March. As of March 31st, there was short interest totaling 34,100 shares, a drop of 19.2% from the March 15th total of 42,200 shares. Based on an average daily volume of 34,300 shares, the days-to-cover ratio is currently 1.0 days. View Forte Biosciences' Short Interest. When is Forte Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our FBRX earnings forecast. How were Forte Biosciences' earnings last quarter? Forte Biosciences, Inc. (NASDAQ:FBRX) issued its earnings results on Monday, March, 18th. The company reported ($0.04) earnings per share for the quarter. What other stocks do shareholders of Forte Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Forte Biosciences investors own include Trevena (TRVN), Chimerix (CMRX), electroCore (ECOR), Great Panther Mining (GPL), Immunic (IMUX), Infinera (INFN) and Stride (LRN). How do I buy shares of Forte Biosciences? Shares of FBRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:FBRX) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchCould Your Accounts Be Frozen?Allegiance GoldThe Gold Grab of the CenturyColonial MetalsStock-Picking AI Predicts #1 Stock of 2024AltimetryBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe only AI company you should be looking atBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Forte Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.